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REVIEW
Selecting heart failure patients for metabolic interventions
Harmen G. Booij*, Anne M. Koning*, Harry van Goor, Rudolf A. de Boer and B. Daan Westenbrink
University Medical Center Groningen, University of Groningen, Groningen, Netherlands
ABSTRACT
Introduction: Heart failure (HF) has become the cardiovascular epidemic of the century and now
imposes an immense burden on health care systems. While our understanding of the pathophysiology
of HF has increased dramatically, the translation of knowledge into clinical practice has been disap-
pointing. Metabolic dysfunction in HF has been studied for eight decades, but these efforts have not
resulted in effective therapies. This paucity in clinical translation probably results from the variable
contribution of metabolic dysfunction to the underlying heart disease. A major unmet need in cardiac
drug development is therefore the ability to identify a homogeneous subset of patients in whom HF is
driven by a specific mechanism that can be targeted.
Areas covered: The available literature was evaluated to describe maladaptive metabolic perturbations
that occur in failing hearts and may cause metabolic inflexibility, oxidative stress and cardiac energy
depletion. Furthermore, the potential utility of various biomarkers and molecular imaging techniques to
detect and quantify specific metabolic dysfunctions in HF were compared. Finally, the authors propose
ways to utilize these techniques to select patients for specific metabolic interventions.
Expert commentary: Metabolic dysfunction is among the most promising therapeutic targets in HF.
Meticulous patient-selection with molecular imaging techniques and specific biomarkers appears
indispensable for the effective translation of decades of scientific knowledge into clinical therapeutics.
ARTICLE HISTORY
Received 23 August 2016








1. Heart failure: the scope of the problem
Over the past four decades, heart failure (HF) patients have
derived substantial benefits from the advances in our under-
standing of the pathophysiology of this devastating disease.
Multiple fundamental discoveries in cardiovascular biology
have fueled novel treatment paradigms that have successfully
been translated into clinical applications. As a result, HF has
transformed from a simple descriptive entity treated with pallia-
tive measures into a well-defined syndrome that can be treated
with a vast array of life saving drugs, interventions, and devices
[1]. Paradoxically, these advances have done little to reduce the
population disease burden, including its economic impact. For
instance, the rate of hospital admissions for acute HF in the USA
has remained around 1 million per year since the beginning of
the century. While the prognosis of HF has improved, the 5-year
mortality rate is still worse than for most types of cancer [2]. In
fact, HF is currently responsible for one in nine deaths in the USA
and Europe [3]. In 2012, HF affected 2% of the US adult popula-
tion and 9% of those over 60 years of age, and the associated
healthcare costs were estimated at 30.7 billion per year [3]. While
healthcare systems are barely coping with the immense health-
care burden of HF as it is, the prevalence of HF and the associated
costs are projected to increase by 50% within the next 15 years
[3]. HFmay thus be regarded as themost pressing cardiovascular
epidemic of this century. New strategies to treat or prevent HF
are therefore urgently needed.
2. Heart failure therapy: is it time to transcend
neurohormonal blockade?
The evolution of HF treatment is regarded as the epitome of
evidence-based medicine because current pharmacological
regimens have all survived the scrutiny of randomized con-
trolled trials in relatively unselected patient populations. With
some exceptions, all HF patients are treated with the same
drugs and devices irrespective of the underlying disease
mechanism. The ability to treat such a heterogeneous disorder
in such a homogeneous fashion may be explained by the fact
that these drugs essentially target the systemic response to
cardiac failure. Indeed, while HF drugs target very specific
components of the sympathetic nervous system, the renin-
angiotensin system or natriuretic peptide biology, they can
all be regarded as interventions intended to restore the sys-
temic neurohormonal balance. After 15 years without any
progress in HF therapy, the PARADIGM-HF trial recently
demonstrated that the combination of a neutral endopepti-
dase inhibitor with an angiotensin-receptor blocker was super-
ior to the well-established angiotensin converting enzyme-
inhibitor enalapril [4]. As both of these drugs target the neu-
rohumoral system, the PARADIGM-HF trial clearly indicates
that there are still viable treatment targets left within the
neurohumoral system. However, the increasing time-window
between subsequent pharmacological innovations does sug-
gest that we are approaching the asymptote for
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neurohormonal blockade [2]. Accordingly, there is a broad
precedent to refocus drug development efforts from nonse-
lective blockade of the systemic consequences of HF, toward
interventions that target the specific underlying disease
mechanisms within the heart [5].
Over the years, multiple perturbations in the cardiac muscle
have been identified that can cause HF or contribute to dis-
ease progression, including but not limited to altered cardiac
excitation-contraction (EC) coupling, aberrant activation of
signal transduction pathways, and dysfunctional myocardial
metabolism [6–11]. While the role of these mechanisms in
HF development has been firmly established, their contribu-
tion to the underlying disease may vary among HF patients, as
well as during different stages of disease progression within
an individual patient. For instance, the expression and activity
of the key calcium cycling molecule sarcoplasmic reticulum
calcium ATPase (SERCA2a) is not uniformly reduced in myo-
cardial tissue samples from HF patients and the degree of
metabolic dysfunction (as specified below) also varies [11,12].
An intervention that targets a specific myocardial defect will
probably not be effective or may even be harmful in patients
in whom that particular mechanism is not causal. This may be
one of the explanations for the lack-off effect of SERCA2a gene
transfer in the CUPID-II trial, as a reduction in myocardial
SERCA2a expression was not an entry criterion for participa-
tion in this study [13]. Whereas routine interrogation of myo-
cardial SERCA2a expression levels may cross ethical and
practical boundaries, there are ample opportunities to evalu-
ate metabolic dysfunction in HF that could routinely be incor-
porated in trial design for metabolic therapies. In the following
sections, we will therefore discuss major metabolic perturba-
tions in HF and the potential utility of biomarkers and mole-
cular imaging techniques to pinpoint underlying disease
mechanisms and thereby select patients for specific metabolic
interventions.
3. Metabolic dysfunction in Heart failure
The heart pumps 10 tons of blood around the body each day
for which it requires up to 30 times its own weight in adeno-
sine triphosphate (ATP). The cardiac ATP stores are, however,
only sufficient to sustain three heart beats. Cardiac function
and myocardial ATP production are therefore heavily inter-
twined and small perturbations in the provision of carbon-
based fuels and the efficiency of mitochondrial respiration can
have major consequences for myocardial performance. The
first indication that energy reserves are reduced in HF dates
back more than eight decades, when Herrmann and Decherd
discovered that creatine levels in failing hearts are reduced
[14]. Based on these observations, it was hypothesized that
energy deprivation leads to cardiac dysfunction, equivalent to
an engine running out of fuel [11]. With few exceptions, the
majority of the evidence gathered since then has supported
this hypothesis. In the following paragraphs, we will provide
an overview of the major metabolic changes that occur in the
failing heart and briefly mention metabolic therapies that are
in various stages of clinical development. Current therapeutic
concepts to restore cardiac metabolism are summarized in
Figure 1.
3.1. Cardiac substrate preference
The heart has considerable metabolic flexibility as it can trans-
form chemical energy stored in various carbon-based substrates,
including fatty acids, glucose, lactate, ketones, and amino acids,
into ATP through oxidative phosphorylation [15]. In healthy
Figure 1. Therapeutic concepts to restore metabolic dysfunction in heart failure.
Simplified schematic depicting cellular energy metabolism from substrate utilization to oxidative phosphorylation and energy transfer to the sites of energy
consumption. Current therapeutic concepts to improve energetic efficiency in heart failure either target proportional substrate use by decreasing fatty acid
metabolism (left panel), increasing glucose oxidation (right upper panel), or augmenting energy transfer (right lower panel). ADP: adenosine diphosphate;
ATP: adenosine triphosphate; CPT: carnitine palmitoyltransferase; Cr: free creatine; FFA: free fatty acids; GLUT4: glucose transporter 4; PCr: phosphocreatine;
PDH: pyruvate dehydrogenase; MCD: malonyl-CoA decarboxylase; NAD+, NADH: oxidized and reduced forms of nicotinamide adenine dinucleotide; TG: triglycerides;
β-ox: beta oxidation.
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resting myocardium, 60–90% of the total ATP production is
derived from β-oxidation of fatty acids. The second major fuel
is pyruvate, which can be generated by glycolysis or lactate
oxidation. During exercise as well as the initial stages of most
cardiac pathologies, the heart shifts from fatty acids to glucose as
the primary source of energy. This shift in substrate preference is
generally considered to be protective as it improves the stoichio-
metric ratio of oxygen consumption to ATP production [16]. β-
oxidation of fatty acids also promotes uncoupling of the proton
motive force generated by the mitochondrial respiratory chain
and ATP synthesis, thereby reducing oxygen utilization efficiency
even further [10,17]. While the amount of energy generated per
gram of substrate is higher for fatty acids compared to carbohy-
drates, the oxygen utilization efficiency is much more favorable
for pyruvate- than for β-oxidation [17].
An additional aspect favoring carbohydrate metabolism in
failing hearts is that two ATP molecules are generated anae-
robically within the cytosol during glycolysis, i.e. the transfor-
mation of glucose into pyruvate. Glycolysis is the only source
of ATP production under hypoxic conditions, but it is very
inefficient as the net ATP yield is about 8% of that obtained
from oxidative phosphorylation of pyruvate. In advanced HF,
glycolytic enzymes and glycolytic activity are markedly
induced while the mitochondrial capacity to oxidize pyruvate
and other major fuels becomes impaired. This phenomenon
results in uncoupling of glycolysis and glucose oxidation and
promotes anaerobic glycolysis as the primary cardiac route of
ATP production [18]. Because anaerobic glycolysis is an ineffi-
cient pathway for energy production, augmentation of glyco-
lysis further aggravates the myocardial energy deficit.
Accordingly, cardiac ATP depletion typically develops when
glucose oxidation diminishes, and increased levels of circulat-
ing pyruvate and lactate can be detected in plasma samples of
HF patients at this point [19–21].
The reductions in glucose oxidation in advanced HF are at
least partially caused by mitochondrial damage or dysfunction
(discussed below). In addition, a functional block at the level
of the pyruvate dehydrogenase (PDH) complex has also
emerged as a central driver of this process [17]. PDH is con-
sidered the rate-limiting step in glucose oxidation as it trans-
forms pyruvate into acetyl-CoA, which subsequently enters
the Krebs cycle. The negative regulator of PDH, PDH kinase,
is strongly activated in failing hearts essentially blocking the
cardiac capacity to oxidize carbohydrates [22]. It must be
stressed, however, that these metabolic adaptations are not
exclusive to cardiomyocytes or HF models as they occur in
virtually all cell types subjected to hypoxic or metabolic stress
[23]. Furthermore, while the data from animal experiments are
more or less consistent, there is a large variation in substrate
utilization in patients with cardiac hypertrophy or HF [19,20].
Finally, comprehensive metabolomics profiling recently indi-
cated that the failing heart relies more on ketone bodies than
on pyruvate, suggesting that advances in biochemical techni-
ques may further refine contemporary paradigms [24]. In sum-
mary, the initial stages of pathological cardiac stress are
accompanied by a marked augmentation of glycolysis and
glucose oxidation, while advanced HF is associated with a
reduced capacity to metabolize all major fuels and increased
dependence on anaerobic glycolysis.
3.2. Oxidative stress in Heart failure
Oxidative stress is another key element of the pathophysiol-
ogy of HF. Since the metabolic changes in HF are inextric-
ably linked to the production of reactive oxygen species
(ROS) by mitochondria, oxidative stress can be a cause as
well as a consequence of HF. Even under physiological
conditions, mitochondria produce superoxide (O2
−) as a
by-product of respiration [25]. Preferably, this free radical
is broken down to water by manganese-dependent super-
oxide dismutase (MnSOD) and nicotinamide adenine dinu-
cleotide phosphate (NADPH)-dependent enzymatic
reduction [25]. In HF, defective EC coupling and mitochon-
drial ion homeostasis impede activation of the Krebs cycle
[26]. This not only disturbs regeneration of NADH to supply
the electron transport chain (ETC) with electrons, but also
that of NADPH required for adequate antioxidant capacity
[26]. The consequent oxidative stress leads to a vicious
circle in which oxidative damage to mitochondrial DNA
causes increased electron leakage from the ETC and oxida-
tion of proteins contributes to further derangement of EC
coupling [26,27]. Adaptive changes associated with HF,
including activation of the sympathetic nervous system
and the renin-angiotensin-aldosterone system, aggravate
this process by increasing cardiac energy supply-and-
demand mismatch as well as direct stimulation of ROS
production [28,29]. Mitochondrial ROS (mtROS) triggers
increased mitochondrial permeability by activation of the
mitochondrial permeability transition pore, among other
pores and channels, allowing ROS to escape to the cytosol
[30]. On emission, mtROS not only induce oxidative damage
to non-mitochondrial structures, but also stimulate ROS
production by other sources, including NADPH oxidase
(Nox), uncoupled NO synthase (NOS), and xanthine oxidase
(XO) [30]. Reciprocally, ROS produced by these sources pro-
mote the production of mtROS [30]. ROS production in HF is
summarized in Figure 2.
The relative contribution of different cell types remains
unclear and may well vary based on underlying disease
mechanisms. In fact, comorbidity-related proinflammatory
signaling and consequent coronary endothelial inflamma-
tion and ROS production have been implicated in the
pathophysiology of HF with a preserved ejection fraction
(HF-pEF), whereas in HF with a reduced ejection fraction
(HF-rEF) ROS are assumed to primarily originate from cardi-
omyocytes [31]. Reflecting the heterogeneous nature of HF
pathology, these variations in ROS production emphasize
the need for a personalized approach to improve the treat-
ment of patients suffering from this syndrome.
3.3. Mitochondrial dysfunction and myocardial energy
depletion
Mitochondria from failing hearts exhibit major structural and
functional defects that diminish their capacity to generate ATP
and increase superoxide release from the respiratory chain.
The activity of respiratory chain complexes and ATP synthase
is significantly decreased in HF and the sensitivity to endo-
genous regulators of oxidative phosphorylation becomes
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diminished [32]. The contribution of mitochondria to other
cellular processes such as cardiac calcium handling, cellular
signaling, and the regulation of cell death also becomes
severely perturbed [33]. Mitochondrial defects are generally
considered to result from ROS-mediated damage to mitochon-
drial DNA and proteins. However, uncontrolled activation of
mitochondrial signaling pathways, transcriptional mitochon-
drial reprogramming, and reduced elimination of damaged
mitochondria by defective mitophagy are now increasingly
recognized as additional causal factors [10,34,35].
Nevertheless, current pharmacological strategies to alleviate
mitochondrial dysfunction are primarily designed to attenuate
mitochondrial oxidative stress with mitochondria-targeted
antioxidants, such as Szeto-Schiller peptide (SS-31) and
MitoQ [36,37]. Further advances in our understanding of mito-
chondrial regulatory mechanisms in HF may provide novel
treatment paradigms that will allow us to specifically target
the underlying disease mechanisms rather than its conse-
quences. For instance, the endogenous regulation of ATP
synthase is still poorly understood and several key regulatory
mechanisms have only recently been discovered [38–40].
The transport of ATP from mitochondria to the sites of ATP-
consumption within the cell is facilitated through the creatine
kinase (CK) shuttle. To allow effective diffusion of energy
throughout the cell, one phosphate group is transferred
from ATP to creatine by mitochondrial CK to generate phos-
phocreatine. Phosphocreatine rapidly diffuses throughout the
cell and ATP is subsequently regenerated from phosphocrea-
tine by CK at the sites of ATP consumption. In addition to the
catalysis of ATP transfer, the CK shuttle also acts as a cellular
energy buffer. Whereas cardiac ATP levels only drop in the
more advanced stages of HF, an energy deficit expressed as
the phosphocreatine/creatine ratio, already becomes apparent
before overt cardiac dysfunction develops [41]. Accordingly,
the energy status of the heart can be expressed as the phos-
phocreatine/creatine ratio. As described above, the energy
depletion hypothesis in HF was based on creatine depletion
in failing hearts, perhaps making this the best-studied meta-
bolic defect in HF. Despite eight decades of research and
several clinical trials, there are no therapies that can specifi-
cally restore cardiac energy levels or ATP transfer [42]. For
instance, creatine supplementation failed to alleviate HF
development in multiple clinical scenario’s [43,44]. The impor-
tance of the cardiac CK shuttle was recently scrutinized in a
mouse model of systemic creatine knockdown. While the
hearts of these mice were fully depleted of creatine, cardiac
function and exercise performance were not altered [45].
Despite the lack of successful interventions in ATP transfer
mechanisms, and the debate surrounding its physiological
relevance, the phosphocreatine/creatine ratio may still prove
Figure 2. Oxidative stress in heart failure: mechanisms, markers and therapeutic concepts.
Simplified representation of the mechanisms causing oxidative stress in HF. MtROS production is linked to metabolic dysfunction through defective mitochondrial
Ca2+ homeostasis. This impedes activation of the Krebs cycle, which in turn disturbs regeneration of NADH to supply the ETC with electrons and NADPH required for
adequate antioxidant capacity. The consequent oxidative stress leads to a vicious circle of increased O2
− leakage from the ETC and aggravated metabolic
dysfunction. MtROS stimulates ROS production by cytosolic sources (cROS) and vice versa. The contribution of specific cell types, such as endothelial cells (producing
eROS) may vary based on underlying disease mechanisms. Plasma and urine markers of oxidative stress are listed in the left panels. Therapeutic targets include O2
−
leakage (lower right panel), XO (middle right panel) and thiol capacity (upper right panel). ADP: adenosine diphosphate; ATP: adenosine triphosphate; Ca2+: calcium
ions; cROS: cytosolic ROS; eROS: endothelial ROS; ETC: electron transport chain; GSH, GSSG: reduced and oxidized forms of glutathione; H2O: water; H2O2: hydrogen
peroxide; H2S: hydrogen sulfide; MDA: malondialdehyde; MnSOD: manganese-dependent superoxide dismutase; MPO: myeloperoxidase; mtROS: mitochondrial ROS;
NAC: N-acetylcysteine; NAD+, NADH: oxidized and reduced forms of nicotinamide adenine dinucleotide; NADP+, NADPH: oxidized and reduced forms of nicotinamide
adenine dinucleotide phosphate; NO: nitric oxide; NOS: NO synthase; Nox: NADPH oxidase; oxLDL: oxidized low-density lipoprotein; ROS: reactive oxygen species;
TMAO: trimethylamine-N-oxide; TRXr, TRXo: reduced and oxidized forms of thioredoxin; O2
−: superoxide; XO: xanthine oxidase; -SH: thiol.
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valuable as a biomarker to select patients for metabolic
interventions.
4. Biomarkers for metabolic dysfunction in Heart
failure
4.1. Biomarkers for cardiac substrate preference and
energy depletion
As described above, severe perturbations in cardiac glucose
oxidation in advanced HF are associated with increased circu-
lating lactate and pyruvate levels and these biomarkers have
been used to monitor metabolic interventions in the past [46].
Nevertheless, such biomarkers to monitor myocardial sub-
strate preference have limited sensitivity and specificity as
they reflect a combination of nutritional intake, gastrointest-
inal uptake, and systemic substrate utilization in all organs.
Likewise, it will be very hard to untangle cardiac and extra-
cardiac contributions to circulating levels of markers for ATP
depletion, such as circulating ADP or AMP levels. Advances in
metabolomics profiling have more recently been adopted to
discover biomarkers with higher specificity for cardiac energy
homeostasis. For instance, long-chain acylcarnitines have
emerged as very promising biomarkers for disrupted β-oxida-
tion, but require further validation [47,48]. A more direct
approach to evaluate cardiac substrate utilization is the com-
parison of metabolite levels in aortic and coronary sinus blood
samples, which allows more detailed analysis of cardiac sub-
strate use, including metabolic substrate flux and ATP produc-
tion efficiency [49]. The obvious drawback of this technique is
the invasive nature and this type of analysis is typically
reserved to monitor the effect of invasive procedures such as
cardiac resynchronization therapy.
4.2. Biomarkers for oxidative stress
As extensively described elsewhere, several biomarkers are
commonly used to assess oxidative stress in HF. These include
oxidized low-density lipoprotein, malondialdehyde, and mye-
loperoxidase in plasma, and isoprostane in plasma and urine
[50]. The gut microbe-generated metabolite trimethylamine-
N-oxide (TMAO), which is adversely associated with HF prog-
nosis, has also been proposed to be related to oxidative stress
[51]. Some of these traditional biomarkers, particularly alde-
hydes, have been suggested to further increase ROS forma-
tion, although studies on their role in pathophysiologiology of
cardiovascular diseases (CVDs) are conflicting [50]. Aldehydes
are formed during many processes including lipid peroxida-
tion [52]. During HF, increased ROS production decreases the
activity of aldehyde dehydrogenase 2 [53]. This causes an
accumulation of aldehydes, including malondialdehyde and
4-hydroxy-2-nonenal (HNE), which localize to mitochondria
and further increase mitochondrial ROS formation through
reactions with nucleophilic protein residues [52,54,55].
Aldehyde levels can be detected in the plasma and several
studies have indicated that plasma aldehyde levels can serve
as biomarkers for oxidative stress. For instance, lipid peroxida-
tion has been investigated as a biomarker for artherogenesis
[56]. Nevertheless, it should be noted that, regardless of their
pathological significance, aldehydes are products of the reac-
tion of ROS with lipids, and thus arise secondarily to the
process that initiated oxidative stress. Thus, while aldehydes
may serve as biomarkers, it is unlikely that they will serve as a
nodal point for metabolic interventions [50]. Consequently,
these biomarkers can be used as a marker for oxidative stress,
but may not for the selection of patients for specific metabolic
interventions.
4.3. Serum free thiols
Recently, the serum free thiol level regained interest as an
indicator of oxidative stress in the context of chronic HF.
Reactive species can oxidize their targets by reacting with
thiols, i.e. functional groups composed of a sulfur and a hydro-
gen atom. Because free (or reduced) thiols are readily oxidized
by reactive species, their level may be seen as a direct reflec-
tion of the balance between oxidants and antioxidant capa-
city, and thus the overall level of oxidative stress [57,58]. What
makes free thiols different from other biomarkers is that apart
from reflecting the overall level of oxidative stress, thiols are
critical active components of the antioxidant defense, which
may be receptive to therapeutic modulation. So far, most
studies looking into antioxidant machinery have focused on
low-molecular-weight thiols, in particular glutathione and
cysteine. For example, a recent study has shown an associa-
tion between higher cystine (i.e. oxidized cysteine) and lower
glutathione levels and an increased mortality risk of coronary
artery disease patients [59]. However, whereas these low-
molecular-weight thiols are key actors in intracellular antiox-
idant defense, in the extracellular compartment they are
strongly outnumbered by protein thiols [60]. In fact, the single
sulfhydryl group of albumin, the most abundant serum pro-
tein, accounts for the majority of thiols in serum [60]. Hence,
compared to the concentration of low-molecular-weight
thiols, the total free thiol level may be a more relevant circu-
latory biomarker of oxidative stress.
Depletion of circulatory free thiols has been shown in
patients with CVD, including acute myocardial infarction
[57,61,62]. Also, thiol oxidation has been linked to established
CVD risk factors, such as aging, smoking, and obesity [63].
Moreover, our group has recently reported a positive associa-
tion between protein-adjusted serum free thiols and a favor-
able disease outcome in a small cohort of 101 stable chronic
HF patients [64]. This finding suggests that serum free thiols
provide a robust reflection of redox status and warrants con-
firmation in a larger cohort.
4.4. Gaseous signaling molecules NO and H2S
Reversible oxidative modifications of protein thiols by several
small molecules may protect proteins from irreversible oxida-
tive damage and, in some cases, alter protein function [58].
Among these small molecules are gasotransmitters nitric oxide
(NO) and hydrogen sulfide (H2S).
NO, also known as endothelial-derived relaxing factor, has
long been acknowledged for its versatile role in cardiac phy-
siology [65]. As the alias suggests, it is an important regulator
of vascular tone, among numerous other bodily processes
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[65]. In HF, NO bioavailability is assumed to be reduced
[66,67]. At the same time, increased levels of NO metabolites,
nitrite and nitrate (NOx) have been described in HF, possibly
reflecting impaired renal excretion [68,69]. More recently, H2S
has been recognized as a cardiovascular signaling molecule,
similar to NO. Like NO, H2S is involved in the regulation of
various (patho)physiological processes and features vasodila-
tory, antioxidant, and anti-inflammatory properties [70].
Unfortunately, reliable methods for direct detection of NO
and H2S in biological samples are lacking. Alternatively, quan-
tification of their metabolites – i.e. NOx for NO and thiosulfate
and sulfate for H2S – may be used to evaluate changes in the
metabolism of these gaseous signaling molecules. Naturally,
other factors that may be of influence, such as intake and
renal function, should be considered in this process. To date,
very few studies have looked into concentrations of NO and
H2S metabolites in relation to outcome of CVD. One paper
describes a higher plasma concentration of NOx 24 hours after
onset of ST-segment elevation myocardial infarction to be
associated with an increased risk of one-year all-cause mortal-
ity or rehospitalization [71]. Another study has found both
urinary thiosulfate and sulfate concentrations of renal trans-
plant recipients to be positively associated with a favorable
cardiovascular risk profile and patient survival [72].
5. Molecular imaging of cardiac metabolism
5.1. Positron emission tomography
Positron emission tomography (PET) is a three-dimensional
imaging technique that can monitor biological processes in
vivo through the use of molecules that have been labeled with
positron emitting radionucleotides. PET already has a central
role in clinical cardiac diagnostics, for the evaluation of myo-
cardial perfusion and viability in ischemic heart disease, the
differential diagnostics of cardiomyopathies, and the diagnosis
and risk stratification of endocarditis. PET also holds great
promise for cardiac drug development as virtually every mole-
cule can be modified to be detectable by PET [73]. The most
abundantly used clinical PET tracer, 18F-FDG, was specifically
designed to monitor glycolytic activity and tracers for β-oxida-
tion have also been developed for clinical application. These
tracers accurately monitor changes in glycolysis and β-oxida-
tion in experimental animals, as well as in patients with HF
[74–77]. In particular, 18F-FDG PET is a sensitive marker for
cardiac glucose uptake, and appears to have reasonable accu-
racy for the prediction of a treatment response to various
interventions [78–80]. More studies are, however, required to
further define the utility of PET as a biomarker for cardiac
substrate utilization in HF.
Monitoring and quantification of focal oxidative stress in
tissues has several potential clinical applications and several
PET probes have been developed for the detection of hypoxia
or ROS production, mostly for oncological or for cardiovascular
applications [81–83]. Unfortunately, the cardiac uptake of
these tracers has been disappointing as they provide insuffi-
cient signal intensity to detect the mild hypoxia or ROS pro-
duction in HF. There are, however, several promising novel
tracers in development and these may prove more reliable for
application in HF [84,85]. Of particular interest for ROS mon-
itoring in HF is radiolabeled vitamin C ([11C]Ascorbic acid),
which exhibits ROS-dependent cellular accumulation that
could result in significant augmentation of signal intensity.
Accordingly, PET holds great promise for the selection and
monitoring of patients for metabolic interventions.
5.2. Magnetic resonance spectroscopy
Cardiovascular magnetic resonance imaging (MRI) has emerged
as the primary method for myocardial tissue characterization in
clinical cardiology, but few people realize that MRI is in fact a
molecular imaging technique. Traditional MRI employs the com-
bination of a high magnetic field to align hydrogen nuclei, the
most abundant MR active nuclei in the body, and radio waves
that causes these nuclei to resonate. When hydrogen nuclei relax
from their resonance, they emit radio waves that can be
detected. Differences in relaxation time in various tissues result
in differences in resonance intensity that can be transformed to
create images. These images can be used to evaluate myocardial
tissue characteristics, such as the presence of fibrosis or edema,
and also allows for detailed quantification of cardiac volumes
and function in HF. Nuclear magnetic resonance spectroscopy
(MRS) utilizes the same hardware and radio waves, but rather
than creating an image from the signal that it receives, it detects
distortions in magnetic resonance frequency within the tissue.
This so-called chemical shift results from the interactions among
neighboring nuclei and electrons in the tissue. As specific mole-
cules generate a specific shift in resonance frequency, detailed
analysis of the frequencies can be used to quantify the concen-
trations of various abundant metabolites in tissues.(Figure 3)
MRS can be used to measure the concentrations of molecules
rich in protons (1H) but also less abundant nuclei such as phos-
phorus (31P), carbon (13C), or sodium (23Na). While several meta-
bolites can be detected with MRS, for human applications, 1H
MRS has primarily been used to detect cardiac creatine and
triglyceride content, 31P MRS to detect cardiac ATP, phospho-
creatine, and phosphocreatine/creatine ratios and 23Na to moni-
tor cardiac sodium content (Figure 3) [86]. Despite its vast
potential, cardiac MRS is a challenging technique as measure-
ments need to be adjusted for cardiac and respiratory motions.
The time required tomeasureMRS spectra varies between 30 sec-
onds and 20 minutes for 1H MRS and 20 and 30 minutes for 31P
MRS, depending on the gating technique and the pulse
sequences employed. Even though it can be performed on
most commercially available scanners, currently, MRS is primarily
used as a research tool in specialized centers. The most com-
monly studied MRS-derived parameters are myocardial triglycer-
ide content and phosphocreatine/creatine ratios [86]. The latter
appears to have remarkable specificity for changes in cardiac
energy stores. For instance, a study in type 2 diabetic patients
was capable of detecting a transient, 12% reduction in cardiac
phosphocreatine/creatine ratio during exercise [87]. MRS has
been used to monitor cardiac energy levels for more than
25 years and can detect changes in high-energy phosphate
levels during treatment [88]. As such, it could be regarded as
the gold standard for the evaluation of energy stores.
The application of MRS as a tool to study cardiac ROS is
limited, although myocardial oxygen levels can be measured
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with MRI using blood oxygen level-dependent sequences [89]. In
theory, 13C MRS holds a vast potential for metabolic imaging
because cellular energy is derived from carbon-based fuels.
Unfortunately, the clinical application of native 13CMRS is limited
by the low abundance and low sensitivity of 13C nuclei to MR
pulses. To circumvent this limitation, a hyperpolarization techni-
que has been developed that can increase the signal of specific
13C-containing molecules by more than 10,000-fold, using a
combination of free radicals and intense freezing under high
magnetic field strengths. These hyperpolarized metabolites are
subsequently injected into the bloodstream and their cardiac
uptake and transformation into downstream metabolites can
be monitored. Hyperpolarization has a short half-life and cannot
be used to enhance native molecules within the heart. It can be
used to monitor metabolic processes in vivo, including the PDH
flux, β-oxidation, and the Krebs cycle [90]. In experimental ani-
mals, hyperpolarized 13C MRS can effectively monitor changes in
substrate utilization during the progression of HF and the effects
of interventions in cardiac substrate utilization [20,91,92].
Regulatory approval of hyperpolarized 13C MRS for application
in humans is pending and, considering its potential, eagerly
anticipated.
In summary, PET is a well-established technique that could
be regarded as the gold standard to monitor cardiac substrate
utilization and is a promising technique for myocardial ROS
detection. Systemic redox status can be measured with circu-
lating and urinary biomarkers, although cardiac specificity
remains limited. MRS is the gold standard for the detection
of cardiac energy levels and holds great promise for the
detection of cardiac substrate utilization through hyperpolar-
ization techniques, but clinical validation is still pending.
Accordingly, we propose that PET should be employed for
patient selection and monitoring when interventions in car-
diac substrate utilization are considered, whereas biomarkers,
such as total serum free thiols, should be used to select
patients for antioxidant treatments. Finally, MRS could be
used to monitor interventions in cardiac ATP production, but
may also serve to monitor the efficacy of other metabolic
interventions. A scheme depicting the potential value of bio-
markers, PET, and MRS to select HF patients for metabolic
interventions during various stages of disease progression is
summarized in Figure 4.
6. Therapeutic interventions in cardiac metabolism
6.1. Therapeutic interventions in cardiac substrate
preference
As the shift from fatty acid to glucose oxidation is generally
considered a physiological adaptation to stress, and several
therapeutic strategies have been developed that aim to pro-
mote glucose oxidation in failing hearts [16]. These drugs
either promote cellular glucose uptake, augment glucose oxi-
dation by restoring PDH complex functionality or inhibit fatty
acid β-oxidation (as summarized in Figure 1 and extensively
reviewed in ref. 17) [17]. While there have been some encoura-
ging improvements in symptoms and exercise performance
Figure 3. Cardiac magnetic resonance spectroscopy.
A, Four chamber and short axis magnetic resonance image of a human heart. The white square depicts the spectroscopic volume that is typically placed in the
intraventricular septum to reduce motion artifacts. B, Typical 1H spectrum of the intraventricular septum. Because water is the most abundant substance, the images
are acquired after a water suppression pulse. C, Typical 31P magnetic resonance spectrum of the left ventricle. D, Typical 13C spectrum of the pig heart obtained after
infusion of a hyperpolarized 1-13C pyruvate tracer. ATP: adenosine triphosphate; 2,3 DPG: 2,3-diphosphoglycerate; PDE: phosphodiesters; PCr: phosphocreatine.
Adapted by permission from BMJ Publishing Group Limited. [Metabolic imaging of the human heart: clinical application of magnetic resonance spectroscopy, HJ
Heart Br. Card. Soc., Bizino MB, Hammer S, Lamb, 100:881–890, 2014.] [86].
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with these drugs such as dicholoracetate and etomoxir, phase
III clinical trials have been neutral or were stopped early due
to drug toxicity or increased HF events [17,93–96]. While this
might be regarded as proof that reductions in glucose oxida-
tion reflect an adaptive mechanism or that the therapeutic
interventions were poorly designed, it should be borne in
mind that defective cardiac substrate utilization was not an
inclusion criterion for these studies. In selected patients, the
outcomes of these studies may have been positive.
6.2. Therapeutic interventions to alleviate myocardial
oxidative stress
As outlined above, excess ROS production is a key factor in the
pathophysiology of HF. At the same time, redox signaling is an
integral part of physiology and lower levels of ROS are
involved in all kinds of beneficial cellular processes, including
immunity, cell growth, and apoptosis [97]. Besides, recurrent
episodes of oxidative stress have been found to upregulate
endogenous antioxidant mechanisms, which in turn may pro-
mote health and longevity [97]. Thus, disturbance of the
physiological functions of ROS is likely to have contributed
to the contradicting findings of studies evaluating uncon-
trolled and untargeted antioxidant therapies, including
N-acetylcysteine (NAC) and vitamins, in cardiac disease
[98,99]. Also, when a specific ROS producing component is
disarmed, this may adversely affect other parts of the redox
network. For example, this may in part explain the disappoint-
ing results of treatment with an XO inhibitor in HF, as this
substance prevents XO from producing O2-, but also decreases
NO production [100]. Perhaps, combination therapy of an XO
inhibitor and an NO donor can resolve this problem. Moreover,
physiological regulatory processes may prevent administered
antioxidants from reaching adequate bioavailability, unless
there is a deficiency to overcome [97]. Finally, oxidation of
an antioxidant substance before or during ingestion may not
only abate its efficacy, but in fact induce oxidative stress [97].
Despite these challenges, in patients with aberrant endo-
genous antioxidant capacity, antioxidant therapies may well be
beneficial. For example, restoring redox status by therapeutic
modulation of free thiols may hold promise to improve disease
outcome in HF. Indeed, in multiple clinical trials, the cysteine
derivative NAC has been shown to both directly reduce dis-
ulfide bonds and act as a glutathione precursor [101]. Other
thiol compounds, with similar modes of action, have also been
described [102]. Although therapeutic results have been incon-
sistent, these compounds may prove to be effective in selected
patients with low free thiol concentrations. Alternatively, phar-
macological stimulation of molecules that induce reversible
protein modifications, including NO and H2S, may offer oppor-
tunities to influence the amount of free thiols, as well as
favorably steer protein function [58,65,70]. One H2S releasing
compound, AP39, may be of particular interest as it is specifi-
cally targeted to mitochondria, one of the most important
sources of ROS in HF. In experimental models, AP39 has been
shown to attenuate H2O2-induced cytotoxicity and to posi-
tively affect vascular tone and intracellular calcium homeosta-
sis [103]. However, further research is needed to prove its
clinical applicability. Other mitochondria-targeted antioxi-
dants, including MitoQ and SS-31, have also shown promise
in experimental HF. Moreover, SS-31 is currently investigated in
a clinical trial focused on myocardial reperfusion injury and a
trial studying this compound it the context of HF will soon
begin [36,104].
7. Conclusions
Metabolic dysfunction is among the most promising therapeu-
tic targets in HF. Meticulous patient selection with molecular
imaging techniques and specific biomarkers appears indispen-
sable for the effective translation of decades of scientific
knowledge into clinical therapeutics.
8. Expert commentary
Although HF patients are treated with up to 5 different
classes of drugs, their mode of action is roughly similar as
they can all be regarded as interventions that restore the
systemic neurohormonal balance. Despite continuous
refinements in this strategy, multiple lines of evidence
Figure 4. Pathological changes and applicability of markers during heart failure
development.
Scheme illustrating the pathological changes and applicability of PET, MRS and
biomarkers to select patients for metabolic interventions during various stages
of HF development. ATP: adenosine triphosphate; HF: heart failure;
MRS: magnetic resonance spectroscopy; PET: Positron Emission Tomography;
ROS: reactive oxygen species.
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indicate that we are approaching the asymptote for added
benefit of neurohormonal interventions. Rather than focus-
ing on the secondary effects of HF, we believe that we
should refocus drug development efforts toward interven-
tions that target specific pathologic changes within the
heart. Despite tremendous advances in our understanding
of the molecular perturbations that occur within the failing
heart, the translation of this knowledge into clinical prac-
tice has been disappointing. The most likely explanation is
that the contribution of a given defect to the underlying
heart disease is highly variable, highlighting the need to
select a homogeneous subset of patients in whom HF is
driven by a specific mechanism that can be targeted. This
is particularly true for myocardial metabolism, which has
been studied for the better part of a century, but has not
proven to be amendable by specific therapeutic interven-
tions. Perhaps the most daunting challenge for metabolic
drug development is the paucity of specific tools to study
cardiac metabolism in an individual patient. Metabolomic
analysis of plasma lacks cardiac specificity and isolation of
cardiac muscle may identify specific metabolic defects, but
cannot be applied to intervention trials, as it requires
ventricular biopsies. Cardiac PET is a highly versatile tech-
nique that allows virtually every molecule to be modified
for detection by PET. Nevertheless, the technique is limited
by variations in signal to noise, the inability to distinguish
tracers from metabolites, and by the fact that it exposes
subjects to ionizing radiation. Another key limitation in
metabolic research in HF is the fact that there is no evi-
dence to support that the level of energy depletion is
causing cardiac dysfunction. It is possible that the meta-
bolic changes in the myocardium reflect beneficial cardiac
adaptation to stress or even an epiphenomenon.
9. Five-year view
Eight decades of metabolic research in HF have not provided
us with reliable metabolic interventions for this devastating
disease. Over the next 5 years, we anticipate that several
metabolic interventions will be tested in clinical trials. One
of the most promising and timely interventions is the mito-
chondria-targeted antioxidant SS-31 (also known as
Bendavia), which has been established as safe and well tol-
erated in patients after an acute myocardial infarction [104].
While a conference abstract indicated that Bendavia is effec-
tive in HF patients as well, appropriately sized trials have not
started yet. We expect that the success of these interventions
depend on the individual degree of mitochondrial dysfunc-
tion and oxidative stress. Accordingly, we believe that the
biomarkers described above should be employed for patient
selection and monitoring. Furthermore, we expect that
hyperpolarized MRS will replace PET as the gold standard
for the assessment of cardiac substrate utilization, as it can
link metabolism to function, differentiate between tracers
and metabolites, and avoids ionizing radiation. Whether bio-
marker-based patient selection will illuminate pathways for-
ward for metabolic interventions in HF remains to be
established.
Key issues
● A major unmet need in drug development for heart failure
is the ability to identify a homogeneous subset of patients
in whom cardiac dysfunction is driven by a specific
mechanism.
● The contribution of metabolic dysfunction and aberrant
production of reactive oxygen species (ROS) tot the under-
lying disease mechanism is highly variable, underscoring
the need for meticulous patient selection.
● Molecular imaging techniques such as magnetic resonance
spectroscopy and positron emission tomography are reli-
able tools to detect a variety of metabolic perturbations in
HF and monitor the effect of interventions.
● Mitochondrial ROS production and the resulting oxidative
stress are both a cause and a consequence of heart failure
that are potentially amendable by therapeutic
interventions.
● Biomarkers for oxidative stress, such as plasma free thiols,
may serve to select patients for antioxidant therapies.
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